Accessibility Menu
Dermata Therapeutics logo

Dermata Therapeutics(NASDAQ) DRMA

Current Price$1.25
Market Cap$5.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-81%
1 Month+9%
Dermata Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.272026-07-20
Dermata Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.93%USD 1.352026-07-13
1 month+8.55%USD 1.172026-06-18
3 month-3.79%USD 1.322026-04-21
Year to date-45.26%USD 2.322025-12-31
1 year-80.59%USD 6.542025-07-18
3 year-99.43%USD 223.502023-07-21
Since inception-99.99%USD 12,455.992021-08-13

Dermata Therapeutics Financials at a Glance

Market Cap

$5.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.10M

EPS (TTM)

-$5.31

P/E Ratio

-0.24

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Price

$1.25

Volume

59,253.241

Open

$1.31

Previous Close

$1.27

Daily Range

$1.20 - $1.33

52-Week Range

$1.10 - $7.50

Estimated Earnings Date

Aug 18, 2026

DRMA News

Foolcom-Featured.png

Dermata Posts Narrower Loss in Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dermata Therapeutics

Dermata develops skincare products for people with acne, psoriasis, and sensitive skin. Its treatments use a freshwater sponge powder to help deliver ingredients. The company aims to make skin care easier with once-weekly applications.

Skin Deep: Products and Services

  • Tome Skincare Line: Direct-to-consumer products for acne, skin renewal, and sensitive skin (0% of revenue in 2025).
  • Foundational Treatment: Once-weekly skin renewal using Spongilla lacustris powder, targeting adults with dull or aging skin (0% of revenue in 2025).
  • Clearing Treatment: Over-the-counter acne system combining sponge powder and salicylic acid wipes for teens and adults (0% of revenue in 2025).
  • Bioneedle Delivery System: Platform for delivering large molecules, such as botulinum toxin, through the skin for medical and cosmetic uses (0% of revenue in 2025).
  • Professional Channel: Planned sales to dermatologists, aestheticians, and med spas (0% of revenue in 2025).

Growth and Expansion: The Dermata Journey

  • Pivoted from prescription drugs to over-the-counter skincare in September 2025.
  • Launched Tome brand and prepared for first product launches in mid-2026.
  • Entered exclusive supply agreement with Reka-Farm LLC for Spongilla raw material (year not specified).
  • Collaborated with Revance Therapeutics for topical botulinum toxin delivery (Phase 2a trial on hold as of 2025).
  • Evaluated in-licensing and acquisition opportunities to expand product portfolio (ongoing as of 2025).

What Makes Dermata Stand Out

Dermata uses a unique freshwater sponge powder to create microchannels in the skin, helping ingredients penetrate more deeply. Its once-weekly treatments differ from daily routines common in the industry. The company relies on exclusive supply agreements and a dual sales approach—direct-to-consumer and professional channels.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 (no commercial sales).
  • Net loss was $7.6 million in 2025, down 38% from 2024.
  • Research and development expenses fell 65% in 2025 from 2024.
  • Cash and cash equivalents were $7.5 million at year-end 2025, up 134% from 2024.

Bottom Line

Dermata is shifting from prescription drugs to consumer skincare, focusing on unique delivery technology. The company remains pre-revenue and faces ongoing operational and funding challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

Gerry Proehl, MBA

Website

www.dermatarx.com

Headquarters

San Diego, CA 92130, US

DRMA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-127.91%

Return on Capital

-124.91%

Return on Assets

-95.14%

Earnings Yield

-4.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.02M

Volume

59.25K

Avg. Volume

68.26K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$7.36M

EBITDA

-$7.22M

Operating Cash Flow

-$8.30M

Capital Expenditure

-$8.00

Free Cash Flow

-$8.30M

Cash & ST Invst.

$6.95M

Total Debt

$0.00

Dermata Therapeutics Performance Analysis

Dermata Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Dermata Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Dermata Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2,087.30-30.8%
20232023-12-31USD -399.81-80.8%
20242024-12-31USD -80.32-79.9%
20252025-12-31USD -8.16-89.8%
Dermata Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3062.9%
Q32025-09-300.6%
Q42025-12-317.9%
Q12026-03-3168.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$567.57K

N/A

Employees

9

N/A

Net Income

-$1.85M

+19.8%

EBITDA

-$1.93M

+16.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.95M

-28.5%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$93.09K

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-95.14%

N/A

Return on Invested Capital

-1.15%

N/A

Free Cash Flow

-$2.48M

-28.2%

Operating Cash Flow

-$2.48M

-28.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
REVBRevelation Biosciences, Inc.
$1.15-0.86%
GTBPGT Biopharma, Inc.
$0.36+5.84%
ARTLArtelo Biosciences, Inc.
$1.13+0.89%
ELABPMGC Holdings Inc.
$1.03-4.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
MARAMara Holdings
$12.19+0.04%
UTZUtz Brands
$14.08+0.89%
IRENIren
$40.56+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.21+0.05%

Questions About DRMA

What is the current price of Dermata Therapeutics?

Dermata Therapeutics is trading at $1.25 per share.

What is the 52-week range for Dermata Therapeutics?

Over the past 52 weeks, Dermata Therapeutics has traded between $1.10 and $7.50.

How much debt does Dermata Therapeutics have?

As of the most recent reporting period, Dermata Therapeutics reported total debt of $0.00.

How much cash does Dermata Therapeutics have on hand?

Dermata Therapeutics reported $6.95M in cash and cash equivalents in its most recent financial results.

What is Dermata Therapeutics’s dividend yield?

Dermata Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services